BCL2L1 and B-cell chronic lymphocytic leukemia: For instance, idelalisib induces apoptosis in chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL) by destabilizing Mcl-1 and Bcl-xL, highlighting its pro-death efficacy in hematologic malignancies.